Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10542427
Filing Date		2006-03-09
First Named Inventor	Kım	
Art Unit		1645
Examiner Name		
Attorney Docket Numb	er	5252YU-1

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	6303136		2001-1	0-16	Lietal.					
If you wis	h to a	d additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where les or Relev	
	1										
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication	citation	n information p	lease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	or	where Rele	or Relevant	+=
	1										
If you wis	h to a	d additional Foreign F	atent Do	cument	citation	information pl	ease click the Add	button	Add		_
			NON	-PATE	NT LITE	RATURE DO	CUMENTS	_	Remove		
Examiner Cite Initiats* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						catalog, etc), o					Τs

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10542427
Filing Date		2006-03-09
First Named Inventor	Kım	
Art Unit		1645
Examiner Name		
Attorney Docket Numb	er	5252YU-1

	1	Intern	stronal Search Report dated April 14, 2004, for PCT Application No. PCT/KR2004/0000	954			
	2	Writter	n Cpinion dated April 14, 2004, for PCT Application No. PCT/KR2004/000054.				
	3		s,Y, et al., "Tissue-Engineered Composities of Bone and Cartilage for Mandible Condyl axillorac Surg, February 2001, Vol. 59, pp. 185-190	ar Reconstruction* J.			
	4 ISHAUG-RILEY, S.L. et al., "Three-dimensional culture of rat calvarial osleoblasts in porous biodegradable polymers" Bornaterials, August 1998, Vol. 19, pp. 1405-1412.						
	PARTRIDGE, K. et al., "Adenoviral BMP-2 Gene Transfer in Messenchymal Stem Cells: In Vitro and in Vivo Formation on Biodegradable Polymer Scalfolds' Biochemical and Biophysical Research Communications, March 22, 2002, Vol. 2002, pp. 144-152						
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							
Examiner	Signa	ture	Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a							

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MIPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reion of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. Applicant is to place a check mark here if English language translation is attached

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10542427
Filing Date		2006-03-09
First Named Inventor	Kım	
Art Unit		1645
Examiner Name		
Attorney Docket Numb	er	5252YU-1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information disclosure statement, See 37 CFR 1.97(e)(1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c)

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Paul S. Cha/	Date (YYYY-MM-DD)	2006-09-12
Name/Print	Paul S. Cha	Registration Number	54022

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.